After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Karyopharm Therapeutics Inc (KPTI) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.037, or -4.74%, to $0.743. The Karyopharm Therapeutics Inc has recorded 24,495 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Karyopharm to Participate at Upcoming Investor Conferences.
KPTI belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $0.78 and fluctuated between $0.7800 as its day high and $0.7015 as its day low. The current market capitalization of Karyopharm Therapeutics Inc is $89.33M. A total of 0.71 million shares were traded on the day, compared to an average of 1.23M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, KPTI has seen 1 BUY and 6 SELL insider trades, representing the acquisition of 41,140 and the disposition of 25,427 shares. Over the last 12 months, there were 8 BUYs and 30 SELLs from insiders. Insiders purchased 813,140 shares during that period but sold 152,002.
In the most recent transaction, Paulson Richard A. sold 3,606 shares of KPTI for 0.92 per share on Nov 06. After the transaction, the President and CEO now owns 791,201 company shares. In a previous transaction on Oct 04, Paulson Richard A. sold 3,589 shares at 1.27 per share. KPTI shares that President and CEO owns now total 794,807.
Among the insiders who bought shares, BOHLIN GAREN G acquired of 41,140 shares on Sep 12 at a per-share price of $1.22. This resulted in the Director holding 45,140 shares of KPTI after the transaction. In another insider transaction, Paulson Richard A. sold 3,622 shares at $1.33 per share on Sep 05. Company shares held by the President and CEO now total 798,396.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for KPTI in the last 3 months, the mean price target is $5.50 with high estimates of $10.00 and low estimates of $3.00. In terms of 52-week highs and lows, KPTI has a high of $5.42 and a low of $0.67.
As of this writing, KPTI has an earnings estimate of $M-tron Industries, Inc. per share for the current quarter. EPS was calculated based on a consensus of Karyopharm Therapeutics Inc. estimates, with a high estimate of $SPDR Portfolio Intermediate Ter per share and a lower estimate of $OPTEC INTERNATIONAL INC.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. KPTI’s latest balance sheet shows that the firm has $228.62M in Cash & Short Term Investments as of fiscal 2021. There were $169.29M in debt and $73.72M in liabilities at the time. Its Book Value Per Share was -$0.88, while its Total Shareholder’s Equity was -$79.67M.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for KPTI is Buy with a score of 4.10.